Clostridioides Difficile Infection Treatment Market, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Clostridiodes Difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through the fecal-oral route. The severe infection of clostridium difficile infection is watery diarrhea, abdominal cramping, and pain, which may be severe, dehydration, rapid heart rate, increased white blood cell count, nausea, and kidney failure. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare-associated infection with clinical manifestations ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. Limited types of drugs such as metronidazole, fidoxamicin, and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in the abdominal wall, patients undergo surgery for the removal of the infected portion. The high prevalence of this disease and occasional disease outbreaks in emerging economies is expected to drive the growth of clostridioides difficile infection treatment market. However, alternative therapy for a broad-spectrum antibiotic such as cephalosporins or fluoroquinolone will hinder the growth of Clostridioides difficile Infection treatment market .

Market Dynamics

Increasing awareness campaigns by several government and non-government organizations are expected to play important role in driving the growth of the global clostridioides difficile infection treatment market growth for the forecast period. For instance, in December 2020, launched by Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer, a not-for-profit corporation, announced that they have acomplished their objective by reaching more than 250,000 Americans to spread awareness regarding Clostridium Difficile. The organization launched the 'See C. diff' to commemorate C. diff (Clostridium Difficile) awareness campaign in 2019, and reached about 80,000 people.

Furthermore, in March 2021, Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer and a not-for-profit corporation, partnered with Ferring Pharmaceuticals, pharmaceutical company, to help and support patients with clostridioides difficile infection. The partnership between Peggy Lillis Foundation and Ferring Pharmaceuticals helped patients suffering from clostridioides difficile infection through new sponsorship to fund new and existing patient advocacy initiatives.

Moreover, on December 4, 2021, the Peggy Lillis Foundation, announced that they have reached more than 1 million people during C. diff awareness campaign in U. S.

Key features of the study:

• This report provides in-depth analysis of the global clostridioides difficile infection market, and provides market size (US$ 893.4 Million) and compound annual growth rate (CAGR 7.1 %) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global clostridioides difficile infection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Novartis AG, Baxter, ANI Pharmaceuticals, Inc., Mylan N.V., Akorn, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., B. Braun Medical Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical., Apotex Inc., AbbVie Inc., Ferring Pharmaceuticals, Fresenius Kabi USA., Pfizer Inc., Strides Pharma Science Limited., Sanofi., AstraZeneca., Eli Lilly and Company., Actelion Pharmaceuticals Ltd., and Astellas Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global clostridioides difficile infection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clostridioides difficile infection market

Detailed Segmentation:

• Global Clostridioides Difficile Infection Treatment Market, By Drug Type:
  • Vancomycin
  • Metronidazole
  • Fidaxomicin
  • Others (late phase drugs, etc.)
• Global Clostridioides Difficile Infection Treatment Market, By Route of Administration:
  • Oral
  • Injectable
• Global Clostridioides Difficile Infection Treatment Market By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Clostridioides Difficile Infection Treatment Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Novartis AG*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Baxter
  • ANI Pharmaceuticals, Inc.
  • Mylan N.V.
  • Akorn
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • B.Braun Medical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Perrigo Pharmaceutical
  • Apotex Inc.
  • AbbVie Inc.,
  • Ferring Pharmaceuticals
  • Fresenius Kabi USA.
  • Pfizer Inc.,
  • Strides Pharma Science Limited.
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company
  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma

"*" marked represents similar segmentation in other categories in the respective section.